Resultados de procura - Chandiwana, David

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom por Suri, Gaurav, Chandiwana, David, Lee, Adam, Mistry, Rohit

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews por Romano, Carla, Harris, Nimanee, Gnanasakthy, Ari, D’Alessio, Denise, Chandiwana, David

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer por Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Tremblay, Gabriel

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer por Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom por Amdahl, Jordan, Diaz, Jose, Sharma, Arati, Park, Jinhee, Chandiwana, David, Delea, Thomas E.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil por Buehler, Anna Maria, Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Igho-Osagie, Ebuwa

Ligazón do recurso

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer? por Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Shor, Anastasiya, Tremblay, Gabriel

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic... por Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer por Turner, Stuart, Chia, Stephen, Kanakamedala, Hemanth, Hsu, Wei‐Chun, Park, Jinhee, Chandiwana, David, Ridolfi, Antonia, Yu, Chu‐Ling, Zarate, Juan Pablo, Rugo, Hope S.

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer por Fasching, Peter A, Delea, Thomas E, Lu, Yen-Shen, De Boer, Richard, Hurvitz, Sara A, Moynahan, Aaron, Chandiwana, David, Lanoue, Brad, Hu, Huilin, Thuerigen, Astrid, O’Shaughnessy, Joyce

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results f... por Harbeck, Nadia, Franke, Fabio, Villanueva-Vazquez, Rafael, Lu, Yen-Shen, Tripathy, Debu, Chow, Louis, Babu, Govind K, Im, Young-Hyuck, Chandiwana, David, Gaur, Anil, Lanoue, Brad, Rodriguez-Lorenc, Karen, Bardia, Aditya

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer por Tripathy, Debu, Curteis, Tristan, Hurvitz, Sara, Yardley, Denise, Franke, Fabio, Babu, K. Govind, Wheatley-Price, Paul, Im, Young-Hyuck, Pencheva, Radost, Eddowes, Lucy A., Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Lanoue, Brad, Harbeck, Nadia

Ligazón do recurso Ligazón do recurso Ligazón do recurso

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study por Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd

Ligazón do recurso Ligazón do recurso Ligazón do recurso